160 related articles for article (PubMed ID: 33421199)
21. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of prognostic factors among patients with chronic graft-versus-host disease.
Pérez-Simón JA; Afram G; Martino R; Piñana JL; Caballero-Velazquez T; Ringden O; Valcarcel D; Caballero D; Remberger M; de Paz Y; Sierra J; Miguel JS; Hagglund H
Haematologica; 2012 Aug; 97(8):1187-95. PubMed ID: 22371184
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
Chen CT; Liu CY; Yu YB; Liu CJ; Hsiao LT; Gau JP; Chiou TJ; Liu JH; Liu YC
PLoS One; 2017; 12(9):e0185210. PubMed ID: 28934311
[TBL] [Abstract][Full Text] [Related]
24. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
26. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.
Leisenring WM; Martin PJ; Petersdorf EW; Regan AE; Aboulhosn N; Stern JM; Aker SN; Salazar RC; McDonald GB
Blood; 2006 Jul; 108(2):749-55. PubMed ID: 16537799
[TBL] [Abstract][Full Text] [Related]
27. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
28. Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.
Nagler A; Labopin M; Dholaria B; Niittyvuopio R; Maertens J; Poiré X; Cornelissen J; Reményi P; Bourhis JH; Beguin Y; Malladi R; Kerre T; Schroyens W; Savani BN; Mohty M
Blood Adv; 2019 Jul; 3(13):1950-1960. PubMed ID: 31262738
[TBL] [Abstract][Full Text] [Related]
29. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
[TBL] [Abstract][Full Text] [Related]
30. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation.
Zhang H
Transfus Apher Sci; 2020 Jun; 59(3):102743. PubMed ID: 32139282
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Bertz H; Grishina O; Socié G;
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1716-26. PubMed ID: 22713691
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
33. Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.
Yan Z; Chen X; Wang H; Chen Y; Chen L; Wu P; Wang W
Medicine (Baltimore); 2018 Jul; 97(27):e10310. PubMed ID: 29979374
[TBL] [Abstract][Full Text] [Related]
34. Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data.
Crocchiolo R; Saillard C; Signori A; Fürst S; El Cheikh J; Castagna L; Oudin C; Granata A; Faucher C; Devillier R; Crocchiolo D; Sormani MP; Chabannon C; Blaise D
Biol Blood Marrow Transplant; 2013 Apr; 19(4):576-83. PubMed ID: 23270984
[TBL] [Abstract][Full Text] [Related]
35. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients.
Nakasone H; Binh PN; Yamazaki R; Tanaka Y; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kimura S; Kikuchi M; Kako S; Okuda S; Oshima K; Tanihara A; Nishida J; Abe Y; Kanda Y
Blood; 2011 Mar; 117(12):3469-72. PubMed ID: 21258011
[TBL] [Abstract][Full Text] [Related]
36. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Kuzmina Z; Krenn K; Petkov V; Körmöczi U; Weigl R; Rottal A; Kalhs P; Mitterbauer M; Ponhold L; Dekan G; Greinix HT; Pickl WF
Blood; 2013 Mar; 121(10):1886-95. PubMed ID: 23303823
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
Ko SH; Lee JH; Lee JH; Park HS; Choi EJ; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Leuk Lymphoma; 2018 Aug; 59(8):1829-1839. PubMed ID: 29164971
[TBL] [Abstract][Full Text] [Related]
38. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
39. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Qian L; Liu M; Shen J; Cen J; Zhao D
Front Immunol; 2020; 11():598359. PubMed ID: 33324415
[TBL] [Abstract][Full Text] [Related]
40. [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
Wojnar J; Giebel S; Hołowiecka-Goral A; Krawczyk-Kuliś M; Markiewicz M; Stella-Hołowiecka B; Wylezoł I
Pol Arch Med Wewn; 2006 Jul; 116(1):671-7. PubMed ID: 17340974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
